Trials / Completed
CompletedNCT00959335
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
Randomized, Open-Label, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex (Reference) Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- Male
- Age
- 19 Years – 63 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate the relative bioavailability of Bicalutamide 50 mg tablet and Casodex following a 50 mg dose in healthy subjects under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA) | |
| DRUG | Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA) |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2009-08-14
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00959335. Inclusion in this directory is not an endorsement.